JP2023545219A5 - - Google Patents
Info
- Publication number
- JP2023545219A5 JP2023545219A5 JP2023545895A JP2023545895A JP2023545219A5 JP 2023545219 A5 JP2023545219 A5 JP 2023545219A5 JP 2023545895 A JP2023545895 A JP 2023545895A JP 2023545895 A JP2023545895 A JP 2023545895A JP 2023545219 A5 JP2023545219 A5 JP 2023545219A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- independently
- cycloalkyl
- nr4r5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087780P | 2020-10-05 | 2020-10-05 | |
| US63/087,780 | 2020-10-05 | ||
| PCT/US2021/071692 WO2022076973A1 (en) | 2020-10-05 | 2021-10-04 | 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545219A JP2023545219A (ja) | 2023-10-26 |
| JP2023545219A5 true JP2023545219A5 (enExample) | 2024-10-10 |
| JP7826325B2 JP7826325B2 (ja) | 2026-03-09 |
Family
ID=81125544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545895A Active JP7826325B2 (ja) | 2020-10-05 | 2021-10-04 | Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043420A1 (enExample) |
| EP (1) | EP4225741A4 (enExample) |
| JP (1) | JP7826325B2 (enExample) |
| KR (1) | KR20230104782A (enExample) |
| CN (1) | CN116438182A (enExample) |
| IL (1) | IL301740A (enExample) |
| MX (1) | MX2023003996A (enExample) |
| WO (1) | WO2022076973A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3196620A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| CN116063212B (zh) * | 2023-01-28 | 2023-06-27 | 山东国邦药业有限公司 | 一种4-苯硫基-1,2-苯二胺的制备方法 |
| CN119954701B (zh) * | 2024-06-18 | 2026-06-16 | 青岛润农化工有限公司 | 一种丁醚脲的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| JP5122280B2 (ja) | 2004-06-30 | 2013-01-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼのインヒビターとして有用なアザインドール |
| EP2325184A1 (en) * | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| JP2007099640A (ja) | 2005-09-30 | 2007-04-19 | Tsumura & Co | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 |
| FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
| FR3000492B1 (fr) * | 2012-12-28 | 2015-09-11 | Oribase Pharma | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
| US10696687B2 (en) * | 2015-08-20 | 2020-06-30 | Changzhou Jiekai Pharmatech Co., Ltd. | Pyrazolo fused heterocyclic compounds as ERK inhibitors |
-
2021
- 2021-10-04 WO PCT/US2021/071692 patent/WO2022076973A1/en not_active Ceased
- 2021-10-04 US US18/030,205 patent/US20240043420A1/en active Pending
- 2021-10-04 JP JP2023545895A patent/JP7826325B2/ja active Active
- 2021-10-04 KR KR1020237015285A patent/KR20230104782A/ko active Pending
- 2021-10-04 EP EP21878712.5A patent/EP4225741A4/en active Pending
- 2021-10-04 IL IL301740A patent/IL301740A/en unknown
- 2021-10-04 MX MX2023003996A patent/MX2023003996A/es unknown
- 2021-10-04 CN CN202180081403.1A patent/CN116438182A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546352A5 (enExample) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2024516972A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| RU2016141052A (ru) | Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| PH12015500488B1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| RU2013147823A (ru) | (альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний | |
| JP2014525464A5 (enExample) | ||
| RU2010150786A (ru) | Пирролопиридины как ингибиторы киназы | |
| JP2020534373A5 (enExample) | ||
| JP6968080B2 (ja) | ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法 | |
| PT1446124E (pt) | Terapia de combinação compreendendo zd6474 e um taxano | |
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2017525740A5 (enExample) | ||
| JP2006502132A (ja) | 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用 | |
| JP2021523169A5 (enExample) | ||
| JP2023553532A5 (enExample) | ||
| JP2008514577A (ja) | Ｚｄ６４７４及びイマチニブを含んでなる組合せ | |
| JP2023531970A5 (enExample) | ||
| JP2024125139A5 (enExample) | ||
| JP7826325B2 (ja) | Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物 | |
| JP2017506267A5 (enExample) |